Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small celllung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-basedchemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamousand non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition hasshown promising results in treatment naïve patients with high tumor mutational burden (TMB). Of note, thepresence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has littlebenefit from immunotherapy combinations and for whom the best treatment option may still be platinum-basedchemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity inEGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns inboth EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumabin combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment optionupon progression to first line tyrosine kinase inhibitors.

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out / C. Proto, R. Ferrara, D. Signorelli, G. Lo Russo, G. Galli, M. Imbimbo, A. Prelaj, N. Zilembo, M. Ganzinelli, L. Pallavicini, I. De Simone, M. Colombo, A. Sicad, V. Torri, M. Garassino. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 75(2019 May), pp. 39-51. [10.1016/j.ctrv.2019.03.004]

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out

G. Galli;M. Imbimbo;M. Colombo;V. Torri;
2019-05

Abstract

Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small celllung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-basedchemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamousand non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition hasshown promising results in treatment naïve patients with high tumor mutational burden (TMB). Of note, thepresence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has littlebenefit from immunotherapy combinations and for whom the best treatment option may still be platinum-basedchemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity inEGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns inboth EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumabin combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment optionupon progression to first line tyrosine kinase inhibitors.
Chemotherapy; First line treatment; Immunotherapy; NSCLC
Settore MED/06 - Oncologia Medica
28-mar-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0305737219300520-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.03 MB
Formato Adobe PDF
2.03 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Rev27_10_18_I_LINEA_CP_1.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 1.1 MB
Formato Adobe PDF
1.1 MB Adobe PDF Visualizza/Apri
Fig 1 Proto.pdf

accesso aperto

Tipologia: Altro
Dimensione 466.07 kB
Formato Adobe PDF
466.07 kB Adobe PDF Visualizza/Apri
Fig 2 Proto.pdf

accesso aperto

Tipologia: Altro
Dimensione 465.12 kB
Formato Adobe PDF
465.12 kB Adobe PDF Visualizza/Apri
Fig 3 Proto .pdf

accesso aperto

Tipologia: Altro
Dimensione 468.41 kB
Formato Adobe PDF
468.41 kB Adobe PDF Visualizza/Apri
Fig 4 Proto.pdf

accesso aperto

Tipologia: Altro
Dimensione 470.12 kB
Formato Adobe PDF
470.12 kB Adobe PDF Visualizza/Apri
Table 1.pdf

accesso aperto

Tipologia: Altro
Dimensione 641.58 kB
Formato Adobe PDF
641.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/647565
Citazioni
  • ???jsp.display-item.citation.pmc??? 52
  • Scopus 92
  • ???jsp.display-item.citation.isi??? 92
social impact